Insider Selling: Bolt Biotherapeutics (NASDAQ:BOLT) VP Sells $13,209.48 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) VP Sarah Nemec sold 4,077 shares of Bolt Biotherapeutics stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $3.24, for a total value of $13,209.48. Following the sale, the vice president directly owned 17,082 shares of the company’s stock, valued at $55,345.68. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sarah Nemec also recently made the following trade(s):

• On Thursday, September 17th, Sarah Nemec sold 2,922 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.32, for a total value of $9,701.04.
• On Wednesday, September 16th, Sarah Nemec sold 843 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.77, for a total value of $3,178.11.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ BOLT opened at $3.65 on Thursday. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. Bolt Biotherapeutics, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $7.20. The firm has a market capitalization of $7.04 million, a PE ratio of -0.22 and a beta of 1.09. The stock’s 50-day simple moving average is $3.82 and its 200-day simple moving average is $4.28.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. As a group, equities research analysts forecast that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on BOLT shares. Rodman & Renshaw started coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $22.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $14.50.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BOLT. Nan Fung Group Holdings Ltd purchased a new stake in Bolt Biotherapeutics in the second quarter valued at approximately $19,250. Renaissance Technologies LLC boosted its holdings in shares of Bolt Biotherapeutics by 40.3% in the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after acquiring an additional 22,200 shares during the period. Finally, T3 Companies LLC purchased a new position in shares of Bolt Biotherapeutics during the fourth quarter worth approximately $208,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.